Difference between revisions of "NextGen-O2k Exploitation"
From Bioblast
Tindle Lisa (talk | contribs) |
|||
| (4 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{ | {{Oroboros highlights page name}} | ||
{{Template:NextGen-O2k header page name logo}} | {{Template:NextGen-O2k header page name logo}} | ||
| Line 19: | Line 19: | ||
::::'''Project Year 1:''' During the first year of the project we dedicated time to our IP strategy and successfully registered “NextGen-O2k”, “DatLab” and “High-Resolution Respirometry” as EU-trademarks. In addition to IP management and periodic IP Watch to ensure that our Freedom-to-operate (FTO) remains unimpeded, we also increased our distributor engagement. Furthermore, we explored the NextGen-O2k’s potential as a medical device and made progress on its algal biotechnology applications. The final component of WP4 for year one was the preparation for ISO certification and the implementation of new quality control measures. | ::::'''Project Year 1:''' During the first year of the project we dedicated time to our IP strategy and successfully registered “NextGen-O2k”, “DatLab” and “High-Resolution Respirometry” as EU-trademarks. In addition to IP management and periodic IP Watch to ensure that our Freedom-to-operate (FTO) remains unimpeded, we also increased our distributor engagement. Furthermore, we explored the NextGen-O2k’s potential as a medical device and made progress on its algal biotechnology applications. The final component of WP4 for year one was the preparation for ISO certification and the implementation of new quality control measures. | ||
::::'''Project Year 2:''' Year 2 was focused on ensuring processes were in place to deliver high quality and customer satisfaction. This included creating a quality [https://wiki.oroboros.at/images/a/ac/QM_policy_2021-03-01.pdf quality policy statement], QM Handbook and Data Management Plan, as well as carrying out a customer satisfaction survey. Our Distributor Relations Dragon, Feiyuan Zhang, continued to work closely with our distributors keeping them abreast of progress and gaining valuable feedback. IP management and IP watch were continued on a regular basis to ensure that the FTO remained unimpeded and the term “O2k” was registered in the EU. | |||
== Progress and next steps == | == Progress and next steps == | ||
See » [[Talk:NextGen-O2k Exploitation|Track record]] | |||
<br/> | <br/> | ||
<gallery mode=default perrow=4 widths="350px" heights="300px"> | <gallery mode=default perrow=4 widths="350px" heights="300px"> | ||
File: | File:Analytica China 2020 2.jpg|The [[CN Beijing Huawei]] team representing Oroboros Instruments at [[Analytica China 2020 Shanghai CN|Analytica China 2020]]. November 2020 | ||
File:JP Onsite.jpg| | File:Timi in Linz Aug 2020.jpg|[[Komlodi Timea|Timea Komlodi, PhD.]] at an on-site visit in Linz, August 2020 | ||
File: | |||
File:ASMRM & J-mit 2019 Fukuoka JP.jpeg|The Oroboros booth at the ASMRM & J-mit 2019 | File:JP Onsite.jpg|[[Cardoso Luiza HD|Luiza Cardoza, PhD.]] at an on-site visit in Japan, February 2020 | ||
File:ASMRM2021.JPG|Snapshot of the [[ASMRM & J-mit 2019 Fukuoka JP|J-Mit and ASMRM 2019]] | |||
File:ASMRM & J-mit 2019 Fukuoka JP.jpeg|The Oroboros booth at the [[ASMRM & J-mit 2019 Fukuoka JP|ASMRM & J-mit]], October 2019 | |||
File:ORODM1A.jpg|The first [[OroDM01 Innsbruck AT|Distributor Meeting]], July 2019 | |||
|- | |- | ||
</gallery> | </gallery> | ||
Latest revision as of 13:23, 3 April 2022
NextGen-O2k Exploitation
The revolutionary all-in-one instrument to conquer mitochondrial disease.
WP4: Exploitation
Abstract
- Preparation for a successful market launch of the NextGen-O2k.
Achievements
- Project Year 1: During the first year of the project we dedicated time to our IP strategy and successfully registered “NextGen-O2k”, “DatLab” and “High-Resolution Respirometry” as EU-trademarks. In addition to IP management and periodic IP Watch to ensure that our Freedom-to-operate (FTO) remains unimpeded, we also increased our distributor engagement. Furthermore, we explored the NextGen-O2k’s potential as a medical device and made progress on its algal biotechnology applications. The final component of WP4 for year one was the preparation for ISO certification and the implementation of new quality control measures.
- Project Year 2: Year 2 was focused on ensuring processes were in place to deliver high quality and customer satisfaction. This included creating a quality quality policy statement, QM Handbook and Data Management Plan, as well as carrying out a customer satisfaction survey. Our Distributor Relations Dragon, Feiyuan Zhang, continued to work closely with our distributors keeping them abreast of progress and gaining valuable feedback. IP management and IP watch were continued on a regular basis to ensure that the FTO remained unimpeded and the term “O2k” was registered in the EU.
Progress and next steps
See » Track record
The CN Beijing Huawei team representing Oroboros Instruments at Analytica China 2020. November 2020
Timea Komlodi, PhD. at an on-site visit in Linz, August 2020
Luiza Cardoza, PhD. at an on-site visit in Japan, February 2020
Snapshot of the J-Mit and ASMRM 2019
The Oroboros booth at the ASMRM & J-mit, October 2019
The first Distributor Meeting, July 2019
